Rute Vanessa Novais Ferreira

Mr. Rute Vanessa Novais Ferreira

University of Minho, Braga, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Critical Reviews in Microbiology
Verified
Journal Article
Closed access
Cláudia SousaCláudia Sousa
Cláudia Sousa
Rute Vanessa Novais FerreiraRute Vanessa Novais Ferreira
Rute Vanessa Novais Ferreira
Nuno AzevedoNuno Azevedo
Nuno Azevedo
Mónica OleastroMónica Oleastro
Mónica Oleastro
JAJoana Azeredo
Joana Azeredo
Luís D. R. MeloLuís D. R. Melo
Luís D. R. Melo
Helicobacter pylori is the major component of the gastric microbiome of infected individuals and one of the aetiological factors of chronic gastritis, peptic ulcer disease and gastric cancer. The increasing resistance to antibiotics worldwide has made the treatment of H. pylori infection a challenge. As a way to overhaul the efficacy of currently used H. pylori antibiotic-based eradication therapies, alternative treatment strategies are being devised. These include probiotics and prebiotics as adjuvants in H. pylori treatment, antimicrobial peptides as alternatives to antibiotics, photodynamic therapy ingestible devices, microparticles and nanoparticles applied as drug delivery systems, vaccines, natural products, and phage therapy. This review provides an updated synopsis of these emerging H. pylori control strategies and discusses the advantages, hurdles, and challenges associated with their development and implementation. An effective human vaccine would be a major achievement although, until now, projects regarding vaccine development have failed or were discontinued. Numerous natural products have demonstrated anti-H. pylori activity, mostly in vitro, but further clinical studies are needed to fully disclose their role in H. pylori eradication. Finally, phage therapy has the potential to emerge as a valid alternative, but major challenges remain, namely the isolation of more H. pylori strictly virulent bacterio(phages).

30 April 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Luís D. R. MeloLuís D. R. Melo
Luís D. R. Melo
Rute Vanessa Novais FerreiraRute Vanessa Novais Ferreira
Rute Vanessa Novais Ferreira
ACAna R. Costa
Ana R. Costa
Hugo OliveiraHugo Oliveira
Hugo Oliveira
JAJoana Azeredo
Joana Azeredo
Chronic wounds affect thousands of people worldwide, causing pain and discomfort to patients and represent significant economical burdens to health care systems. The treatment of chronic wounds is very difficult and complex, particularly when wounds are colonized by bacterial biofilms which are highly tolerant to antibiotics. Enterococcus faecium and Enterococcus faecalis are within the most frequent bacteria present in chronic wounds. Bacteriophages (phages) have been proposed as an efficient and alternative against antibiotic-resistant infections, as those found in chronic wounds. We have isolated and characterized two novel enterococci phages, the siphovirus vB_EfaS-Zip (Zip) and the podovirus vB_EfaP-Max (Max) to be applied during wound treatment. Both phages demonstrated lytic behavior against E. faecalis and E. faecium. Genome analysis of both phages suggests the absence of genes associated with lysogeny. A phage cocktail containing both phages was tested against biofilms formed in wound simulated conditions at a multiplicity of infection of 1.0 and a 2.5 log CFU.mL−1 reduction in the bacterial load after at 3 h of treatment was observed. Phages were also tested in epithelial cells colonized by these bacterial species and a 3 log CFU.mL−1 reduction was observed using both phages. The high efficacy of these new isolated phages against multi-species biofilms, their stability at different temperatures and pH ranges, short latent periods and non-cytotoxicity to epithelial cells suggest their therapeutic use to control infectious biofilms present in chronic wounds.

20 October 2022 in Critical Reviews in Microbiology
Verified
Journal Article
Closed access
Cláudia SousaCláudia Sousa
Cláudia Sousa
Rute Vanessa Novais FerreiraRute Vanessa Novais Ferreira
Rute Vanessa Novais Ferreira
SSSílvio Santos
Sílvio Santos
Nuno AzevedoNuno Azevedo
Nuno Azevedo
Luís D. R. MeloLuís D. R. Melo
Luís D. R. Melo
The association of Helicobacter pylori to several gastric diseases, such as chronic gastritis, peptic ulcer disease, and gastric cancer, and its high prevalence worldwide, raised the necessity to use methods for a proper and fast diagnosis and monitoring the pathogen eradication. Available diagnostic methods can be classified as invasive or non-invasive, and the selection of the best relies on the clinical condition of the patient, as well as on the sensitivity, specificity, and accessibility of the diagnostic test. This review summarises all diagnostic methods currently available, including the invasive methods: endoscopy, histology, culture, and molecular methods, and the rapid urease test (RUT), as well as the non-invasive methods urea breath test (UBT), serological assays, biosensors, and microfluidic devices and the stool antigen test (SAT). Moreover, it lists the diagnostic advantages and limitations, as well as the main advances for each methodology. In the end, research on the development of new diagnostic methods, such as bacteriophage-based H. pylori diagnostic tools, is also discussed.

Verified
Journal Article
Open access
PDF file
Rute Vanessa Novais FerreiraRute Vanessa Novais Ferreira
Rute Vanessa Novais Ferreira
Cláudia SousaCláudia Sousa
Cláudia Sousa
RGRaquel F. S. Gonçalves
Raquel F. S. Gonçalves
APAna C. Pinheiro
Ana C. Pinheiro
Mónica OleastroMónica Oleastro
Mónica Oleastro
Luís D. R. MeloLuís D. R. Melo
Luís D. R. Melo
Helicobacter pylori, a significant human gastric pathogen, has been demonstrating increased antibiotic resistance, causing difficulties in infection treatment. It is therefore important to develop alternatives or complementary approaches to antibiotics to tackle H. pylori infections, and (bacterio)phages have proven to be effective antibacterial agents. In this work, prophage isolation was attempted using H. pylori strains and UV radiation. One phage was isolated and further characterized to assess potential phage-inspired therapeutic alternatives to H. pylori infections. HPy1R is a new podovirus prophage with a genome length of 31,162 bp, 37.1% GC, encoding 36 predicted proteins, of which 17 were identified as structural. Phage particles remained stable at 37 °C, from pH 3 to 11, for 24 h in standard assays. Moreover, when submitted to an in vitro gastric digestion model, only a small decrease was observed in the gastric phase, suggesting that it is adapted to the gastric tract environment. Together with its other characteristics, its capability to suppress H. pylori population levels for up to 24 h post-infection at multiplicities of infection of 0.01, 0.1, and 1 suggests that this newly isolated phage is a potential candidate for phage therapy in the absence of strictly lytic phages.

20 May 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Luís D. R. MeloLuís D. R. Melo
Luís D. R. Melo
Rute Vanessa Novais FerreiraRute Vanessa Novais Ferreira
Rute Vanessa Novais Ferreira
ACAna R. Costa
Ana R. Costa
Hugo OliveiraHugo Oliveira
Hugo Oliveira
JAJoana Azeredo
Joana Azeredo
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

3 October 2024 in Microbes and Infection
Verified
Journal Article
Open access
Rute Vanessa Novais FerreiraRute Vanessa Novais Ferreira
Rute Vanessa Novais Ferreira
GPGraça Pinto
Graça Pinto
EPEva Presa
Eva Presa
Mónica OleastroMónica Oleastro
Mónica Oleastro
CSCatarina Carneiro Silva
Catarina Carneiro Silva
Luís D. R. MeloLuís D. R. Melo
Luís D. R. Melo
The increase of antibiotic resistance calls for alternatives to control Helicobacter pylori, a Gram-negative bacterium associated with various gastric diseases. Bacteriophages (phages) can be highly effective in the treatment of pathogenic bacteria. Here, we develop a method to identify prophages in H. pylori genomes aiming at a future use in therapy. A PCR-based technique tested five primer pairs on 74 clinical H. pylori strains. With the PCR screening, 14 strains most likely to carry prophages were fully sequenced. After that, a more holistic approach was taken by studying the complete genome of the strains. The work allowed us to identify 12 intact prophage sequences, which were then characterized concerning their morphology, virulence, and antibiotic-resistance genes. To understand the variability of prophages, a phylogenetic analysis using the sequences of all H. pylori phages reported to date was performed. Using a PCR-based technique we increased the efficiency of identifying complete prophages to 54.1 %. Genes with homology to potential virulence factors were identified in some new prophages. Phylogenetic analysis revealed a close relationship among H. pylori-phages, although there are phages with different geographical origins. This study provides a deeper understanding of H. pylori-phages, providing valuable insights into their potential use in therapy.